Minimising the environmental impact of inhaled therapies

Lauri Lehtimäki, Unnur Björnsdóttir, Christer Janson, Tari Haahtela

Source: Eur Respir J, 55 (5) 2000721; 10.1183/13993003.00721-2020
Journal Issue: May
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Lauri Lehtimäki, Unnur Björnsdóttir, Christer Janson, Tari Haahtela. Minimising the environmental impact of inhaled therapies. Eur Respir J, 55 (5) 2000721; 10.1183/13993003.00721-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers
Source: Eur Respir J, 55 (2) 2000048; 10.1183/13993003.00048-2020
Year: 2020



Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers
Source: Eur Respir J, 55 (5) 2001122; 10.1183/13993003.01122-2020
Year: 2020



Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Estimation of risk of osteoporosis based on inhaled and oral corticosteroids
Source: Eur Respir J 2002; 20: Suppl. 38, 409s
Year: 2002

Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 8s
Year: 2002

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature
Source: Eur Respir J, 52 (4) 1800703; 10.1183/13993003.00703-2018
Year: 2018



Does short-term treatment intensification influence long-term treatment effects on health status in COPD?
Source: Eur Respir J 2005; 26: Suppl. 49, 293s
Year: 2005

Personality influences the reporting of side effects of inhaled corticosteroids
Source: Annual Congress 2008 - Social determinants and psychological issues in primary care respiratory diseases
Year: 2008

Recent trends in inhaled corticosteroid prescriptions and its impact on COPD management: an analysis of the KOLD/KOCOSS cohorts
Source: International Congress 2019 – COPD treatment: cohorts and real-world studies
Year: 2019

Effects of inhaled marijuana exposure on lung health
Source: International Congress 2015 – The evolving marijuana epidemic
Year: 2015



Addition of leukotriene antagonists or long-acting β2-agonists to inhaled corticosteroid therapy in asthma treatment increases drug costs without decreasing service-related costs
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


Mechanisms of systemic side effects of inhaled steroids
Source: Eur Respir J 2004; 24: Suppl. 48, 347s
Year: 2004

Does inhaled corticosteroid use affect the risk of ?COVID-19-related death?
Source: Breathe, 17 (1) 200275; 10.1183/20734735.0275-2020
Year: 2021



Impact of inhaled corticosteroids in patients with cardiovascular disease
Source: Eur Respir Monogr 2020; 88: 251-263
Year: 2020


Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice
Source: Annual Congress 2010 - Management of airway disease
Year: 2010


Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship
Source: Eur Respir J, 55 (1) 1902193; 10.1183/13993003.02193-2019
Year: 2020